Ultra-pure ethyl-eicosapentaenoic acid (ethyl-EPA), a semi-synthetic ethyl ester of eicosapentaenoic acid, is associated with clinical improvement in motor functioning in Huntington's disease. The aim was to determine the extent to which it might reduce the rate of progress of cerebral atrophy. High-resolution cerebral magnetic resonance imaging scans were acquired at baseline, 6 months and 1 year in up to 34 patients with stage I or II Huntington's disease who took part in a randomized, double-blind, placebo-controlled trial of ethyl-EPA. For each subject and each pair of structural images, the two-timepoint brain volume change was calculated in a double-blind manner. Significant group-level reductions in brain atrophy were observed in the head of the caudate nucleus and the posterior thalamus. These findings show that treatment with ethyl-EPA is associated with significant reduction in brain atrophy, particularly in the caudate and thalamus. No other drug tested in Huntington's disease has shown this effect.
Introduction
Huntington's disease (HD) is an autosomal dominant disease of the human brain caused by an unstable expansion of CAG trinucleotide triplet repeats in the huntingtin gene at 4p16.3; the CAG repeats are transcribed and translated into polyglutamine expansion (polyQ) stretches, and the length of the repeats correlates inversely with age of onset. 1, 2 HD is characterized by motor dysfunction, with chorea and incoordination occurring BK Puri, GM Bydder, MS Manku et al. Ethyl-eicosapentaenoic acid in Huntington's disease relatively early, and dystonia, rigidity and bradykinesia becoming more prominent with time; death usually occurs within 15 -25 years of onset of motor symptomatology. 3, 4 The key neuropathological change is neuronal degeneration, particularly in the striatum; mitochondrial dysfunction may be one of the important contributors to this. 5, 6 Although the mechanism of mitochondrial damage in HD is unknown, there is consistent evidence for an involvement of the c-Jun amino-terminal kinase (JNK) pathway induced by stress-signal kinase 1 (SEK1). A rat hippocampal study showed that expression of polyQ huntingtin induces neuronal apoptosis via activation of the SEK1-JNK pathway. 7 In vitro studies of polyglutamine expression in PC12 neuronal cells have demonstrated that polyglutaminecontaining protein fragments accumulate as nuclear aggregates and these accumulate activated SEK1 which, in turn, triggers a celldeath-signalling SEK1-JNK cascade. 8 Additionally, polyQ has been found to induce a protein-damaging stress that triggers activation of JNK and the transcription factor AP-1, through inhibition of JNK phosphatase(s). 9 Furthermore, there is evidence for a specific role for p53 in the mitochondria-associated cellular dysfunction and behavioural abnormalities of HD, linking the nuclear and mitochondrial pathologies. 10 Mutant huntingtin (mHtt) with polyQ binds to p53 and up-regulates levels of nuclear p53 as well as p53 transcriptional activity in neuronal cultures. 10 This augmentation is specific, occurring with mHtt but not mutant ataxin-1 with expanded polyQ. The p53 levels are also increased in the brains of mHtt transgenic (mHtt-Tg) mice and HD patients. 10 Perturbation of p53 prevents mitochondrial membrane depolarization and cytotoxicity in HD cells and decreases respiratory complex IV activity of mHtt-Tg mice, while deletion of the tumour suppressor gene p53 suppresses neurodegeneration in mHtt-Tg flies and neurobehavioral abnormalities of mHtt-Tg mice. 10 Moreover, p53 can transactivate the human and murine HD/Hdh promoters and modify the level of wild-type and mHtt protein, both in vivo and in vitro; successive loss of p53 alleles results in a dose-dependent reduction in the level of mHtt in areas most affected in HD and is accompanied by a parallel increase in proenkephalin mRNA expression in the brain, and a significant increase in nuclear aggregate formation in the striatum. 11 Aggregation of mHtt may be a protective mechanism whereby toxic soluble mHtt is sequestered, so the findings of the increase in aggregate load and the restoration of enkephalin expression suggest a functional rescue of these HD phenotypes by a deficiency in p53. 11 In addition to the JNK pathway, mitochondrial damage may also be mediated by nuclear factor κB (NF-κB), one of the Rel family of transcription factors, which is expressed in neurons and glia throughout the mammalian central nervous system. There is evidence that NF-κB participates in a signalling cascade culminating in the apoptotic demise of rat striatal neurons exposed to the excitotoxin quinolinic acid (QA), an N-methyl-Daspartate (NMDA) receptor agonist. 12, 13 Stimulation of glutamate receptors of the NMDA subtype by QA leads to the selective degradation of IκB-α, a cytosolic protein that binds NF-κB, with the resultant release and nuclear translocation of NF-κB augmenting expression of the pro-apoptotic genes p53 and c-Myc. 14 Eicosapentaenoic acid (EPA; C20:5n-5) is a long-chain polyunsaturated fatty acid of the BK Puri, GM Bydder, MS Manku et al. Ethyl-eicosapentaenoic acid in Huntington's disease n-3 series that is a natural metabolite of the essential fatty acid α-linolenic acid. EPA is a labile substance that can degrade rapidly. Ethyl-EPA is a semi-synthetic, highly purified derivative of EPA which is more stable. After oral administration and absorption, ethyl-EPA is acted on by esterases, particularly pancreatic lipase, to release EPA; thus ethyl-EPA acts as a pro-drug. The cyclo-oxygenase and the lipoxygenase metabolites of EPA include biologically active eicosanoids, such as 3-series prostaglandins and resolvins. 15 EPA also strongly down-regulates interleukin-1β (IL-1β)-induced prostaglandin H synthase 2 (PGHS-2) expression in human microvascular endothelial cells, probably through its 5-lipoxygenase-dependent metabolites. 16 Since prostaglandin biosynthesis can directly induce apoptosis in mammalian neuronal cells, 17, 18 downregulation of the prostaglandin synthesizing enzyme cascade might be associated with a protective effect of EPA against apoptotic changes in the brain.
In respect of the putative pathways of mitochondrial damage in HD, it is of note that not only does EPA target mitochondrial function and affect gene expression by acting on transcription factors, such as peroxisome proliferator-activated receptors (PPARs), 19 but it also acts on the JNK and NF-κB pathways. 20 EPA has been reported to inhibit phorbol 12-tetradecanoate 13acetate-induced JNK-AP-1 transactivation and subsequent cellular transformation in a murine epidermal JB6 cell model, 21 deoxynivalenol-induced JNK activation in murine macrophages, 22 lipopolysaccharideinduced (LPS) JNK activation in murine macrophages, 23 LPS-induced JNK activation in murine BV2 microglia, 24 and amyloid-βinduced JNK activation in rat hippocampus. 25 Similarly, EPA inhibits tumour necrosis factor mRNA expression in LPS-stimulated murine macrophages and LPS-stimulated human monocytes, possibly by reducing NF-κB activation through decreasing the number of P65/P50 NF-κB dimers 26 or by inhibiting the phosphorylation of the inhibitory subunit IκB (which in its non-phosphorylated form normally keeps NF-κB in an inactive form). 24, 27 Furthermore, ultra-pure EPA has been shown to increase brain levels of Nacetylaspartate (NAA), a putative marker of neuronal integrity. 28 In humans, the first open-label studies of an EPA-containing fatty acid intervention showed a beneficial effect on motor function in HD, 29 and this was confirmed by small randomized, double-blind, placebocontrolled trials of EPA-containing fatty acids 30 and of pure ethyl-EPA. 31 A subsequent large-scale randomized, placebocontrolled trial of ethyl-EPA in HD showed that patients in the per protocol group as well as those with a lower CAG repeat number (i.e. those with a relatively late age of onset), showed clinical improvement with ethyl-EPA compared with placebo. 32 The first pilot study of pure ethyl-EPA in HD included a structural brain magnetic resonance imaging (MRI) component before and after intervention. 31 Analysis of these structural MRI scans using a rigid-body sincinterpolation-based subvoxel registration technique showed that, while placebo treatment was associated with progressive cerebral atrophy, this was not the case with the ethyl-EPA intervention. 31 
Patients and methods

PATIENTS
The study was carried out at the MRC Clinical Sciences Centre, Hammersmith Hospital, Imperial College London, UK. All patients had symptomatic, genetically confirmed HD or a family history of HD. The other entry criteria for the study included: being in either stage I (a decline in functional capacity to work with impaired motor function and emotional control, including irritability and depression, but fully able to maintain their own activities of daily living) or stage II (unable to work or drive a car, reliant on family or other carers for activities of daily living but remaining at home with assistance, increasing dysarthria, dysphasia, loss of motor control and cognitive function) 34 of the disease; scoring between 50 (24-h supervision appropriate: assistance required for bathing, eating, toileting) and 90 (no physical care needed if difficult tasks are avoided) on the Independence Scale component of the Unified Huntington's Disease Rating Scale; 35 the availability of a family member or other carer; aged between 30 and 70 years. Participants in the study could be of either gender. Pharmacotherapy with depot antipsychotic medication was an exclusion criterion.
The study was carried out according to the Declaration of Helsinki. Each patient, in the presence of at least one responsible carer, was given both verbal and written explanations of the study, and gave written informed consent to participate. The study had multinational research ethics committee approval from the UK, USA, Canada and Australia. Hammersmith Hospital was the lead centre for which ethics approval was covered by the Hammersmith Hospitals NHS Trust Research Ethics Committee.
TREATMENT RANDOMIZATION
After screening and acceptance into the trial, the patients were assigned to either ethyl-EPA or placebo by receiving a numbered pack supplied by a clinical trials packaging organization (PCI Clinical Services, Bolton, UK), which was independent of all other aspects of the trial. Randomization was stratified in a block size of four and PCI Clinical Services held the randomization code until the database had been closed and all patients had been assigned to groups. The randomization was double-blind; neither the patients nor the participating medical staff had access to this code during the course of the study.
Patients were randomized to receive 2 g/day of either ethyl-EPA (purity > 95%; Amarin Neuroscience Ltd, London, UK) or placebo (light liquid paraffin, a nonabsorbed mechanical laxative), in both cases taken as two 500 mg capsules twice daily for 1 year. The dose of 2 g/day of the placebo was well below the usual laxative dose of 15 -30 g/day. The ethyl-EPA and placebo capsules were of identical appearance.
IMAGING
At baseline, 6-month and 1-year follow-ups, sagittal three-dimensional T 1 -weighted radio frequency spoiled images (repetition time 21 ms, echo time 6 ms, flip angle 35°, 152 × 256 image matrix, 114 slices, 1.6 mm slice thickness, 25 cm field of view) were acquired on a 1.0 T Picker HPQ scanner (Marconi Medical Systems, Cleveland, OH, USA). Phantom measurements were taken regularly during the study to confirm that no changes in magnetic gradient strength had occurred.
GLOBAL BRAIN ATROPHY
For each patient and each pair of T 1 images, the two-timepoint percentage brain volume BK Puri, GM Bydder, MS Manku et al.
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change was estimated with SIENA (Structural Image Evaluation, using Normalization, of Atrophy), version 2.5, 36,37 part of FMRIB Software Library (FSL) version 4.0. 38 FSL is a comprehensive library of analysis tools for Functional MRI, MRI and Diffusion Tensor Imaging brain imaging data. FSL is written mainly by members of the Analysis Group, FMRIB, Oxford, UK.
SIENA starts by extracting brain and skull images from the two-timepoint whole-head input data. 39 The two brain images are then aligned to each other 40, 41 (using the skull images to constrain the registration scaling); both brain images are re-sampled into the space halfway between the two. Next, tissuetype segmentation is carried out 42 in order to find brain/non-brain edge points, and then perpendicular edge displacement (between the two timepoints) is estimated at these edge points. Finally, the mean edge displacement is converted into a global estimate of percentage brain volume change between the two timepoints. Using 16 normal control subjects scanned twice the scan-rescan error rate has been estimated to be in the region of 0.2%, and the longitudinal error rate has also been estimated to be in the order of 0.2%. 37
VOXEL-WISE ANALYSES
For each patient, the edge displacement image (encoding, at brain/non-brain edge points, the outwards or inwards edge change between the two timepoints) was dilated, transformed into the MNI152 standard space (an average T 1 -weighted brain image constructed from 152 normal subjects at the Montreal Neurological Institute, Montreal, Canada) and, subsequently, masked by a standard MNI152-space brain edge image. In this way the edge displacement values were warped onto the standard brain edge.
STATISTICAL ANALYSES
For the estimation of global atrophy, between-group comparisons were carried out using both a standard two-sample t-test within the framework of a general linear model (GLM) and using non-parametric permutation testing. Permutation methods were used here for inference on statistical maps in order to allow for a non-parametric null distribution. Owing to the blind allocation of subjects to the two groups we could assume exchangeability under the null hypothesis. This justified permutation of the data. This approximate permutation test is asymptotically exact, that is the results become more accurate with increased sample size. In theory an exact test arises from evaluating every possible permutation. This, however, was not feasible as in this case there were more than 2.2 billion possible permutations. Instead, a random sample of possible permutations was used, creating a Monte Carlo permutation test. Such a Monte Carlo test is exact on average for large sample sizes and will approximate the results obtained when carrying out all possible permutations. In the case of a large number of possible permutations one can show that a true, exhaustive P-value of p will produce Monte Carlo P-values between p ± 2√(p[1 -p]/n) about 95% of the time, where n is the number of Monte Carlo permutations performed in order to approximate the true P-value p. At a low P-value of P < 0.05, therefore, about 10 000 permutations are required to reduce the margin of error to < 10% of the nominal α. As such, all non-parametric tests involved 10 000 permutations.
For the voxel-wise analyses, the images resulting from warping the edge displacement values onto the standard brain edge were fed into voxel-wise statistical GLM analyses (two-sample t-test); i.e. at every BK Puri, GM Bydder, MS Manku et al.
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voxel the difference in the mean displacement between the two groups was directly compared with the associated variance of displacement values. Final t-statistic maps were converted to voxel-wise P-values and are shown rendered on the MNI152 standard brain template.
Results
PATIENTS
Thirty-four HD patients were scanned in this study at baseline and 6-month follow-up. Thirty of these patients went on to have a 12month follow-up MRI scan. The mean (±SE) age at the time of first MRI scanning of the 16 HD patients randomized to receive ethyl-EPA (51.3 ± 2.5 years) did not differ significantly from that of the 18 patients randomized to receive placebo (48.7 ± 2.2 years). Similarly, the sex ratio of the ethyl-EPA group (male:female ratio, 9:7) did not differ significantly from that of the placebo group (male:female ratio, 8:10).
GLOBAL ATROPHY
The mean changes in percentage global brain volume for both groups over the 1-year period, and also over the first and second 6month periods, are given in Table 1 , together with the corresponding statistical significances calculated according to a standard two-sample t-test within a GLM and non-parametric permutation testing.
Overall, patients treated with ethyl-EPA had a reduced mean rate of atrophy in all comparisons compared with the placebo group. There was no significant effect of age at the time of scanning on these results. Figures 1 and 2 show the results of the voxelwise analyses of ethyl-EPA versus placebo. Areas of significant group-level reduction in brain atrophy between patients receiving ethyl-EPA and those receiving placebo are shown in red-yellow; the colour bar shows the P-value under the null hypothesis of no change. There was a clear significant reduction in global cerebral atrophy in the ethyl-EPA treated group compared with the placebo group during the first 6 months of treatment while, during the second 6-month period, the rate of global atrophy was similar in both groups. In the first 6-month period, the difference was significant adjacent to the ventricles, particularly around the anterior portion of the lateral ventricles. Local analyses also revealed a significant reduction in regional atrophy of the head of the caudate nucleus and the posterior 
VOXEL-WISE ANALYSES
Discussion
HD is a severe neurological disorder with progressive cerebral atrophy and a poor prognosis. The results from the voxel-wise analyses of the present study were consistent with the global atrophy estimates: subjects treated with ethyl-EPA showed a significantly reduced rate of atrophy over the first 6 months. Local analyses also revealed a significant reduction in regional atrophy of the head of the caudate nucleus and the posterior thalamus for the 0 versus 12 months comparison: atrophy of the head of the caudate nucleus is a characteristic neuropathological feature of HD, 43 while atrophy of microneurons (internuncial cells) occurs in the thalamus. 44 Given the involvement of both these structures in the motor abnormalities (including chorea) that occur in HD, 45 the results of the present study are consistent with the observation in the same subjects that the clinical beneficial effects of ethyl-EPA in the patients of the per protocol cohort was mainly the result of changes in chorea and a modified motor score (without chorea and dystonia items). 32 It is noteworthy that recent cerebral MRI studies have indicated that changes in volume are useful biomarkers of the progression of HD. 46 -48 We hypothesize that the mode of action of ethyl-EPA in HD may involve targeting mitochondrial function and affecting gene expression by acting on transcription factors such as PPARs, 19 and also acting on the JNK and NF-κB pathways. 20 Interestingly, in the rat brain EPA has been found to abrogate LPSinduced inhibition of long-term potentiation, block LPS-induced decrease in hippocampal concentrations of the cytokines IL-10 and IL-4, and up-regulate PPAR-γ (which has known anti-inflammatory actions). 49 Furthermore, preliminary evidence indicates that treatment of bipolar disorder patients with ethyl-EPA is associated with increased levels of NAA in the corpus callosum which, given that the amino acid-derivative NAA is considered to be a marker of neuronal integrity, is consistent with a possible neurotrophic role of EPA. 28 In conclusion, treatment with ethyl-EPA was shown to be associated with significant reduction in brain atrophy, particularly in the caudate and thalamus. No other drug tested in HD has so far been shown to have this effect. 
